Recombinant human lecithin‐cholesterol acyltransferase Fc fusion: Analysis of N‐ and O‐linked glycans and identification and elimination of a xylose‐based O‐linked tetrasaccharide core in the linker region |
| |
Authors: | Chris Spahr Justin J. Kim Sihong Deng Paul Kodama Zhen Xia Jay Tang Richard Zhang Sophia Siu Noi Nuanmanee Bram Estes Jennitte Stevens Mingyue Zhou Hsieng S. Lu |
| |
Affiliation: | 1. Biologics Optimization, Therapeutic Discovery, Amgen Inc., , Thousand Oaks, California, 91320;2. Drug Substance Development, Amgen Inc., , Seattle, Washington, 98119;3. Protein Technologies, Therapeutic Discovery, Amgen Inc., , South San Francisco, California, 94080;4. Biologics Optimization, Therapeutic Discovery, Amgen Inc., , Seattle, Washington, 98119;5. Metabolic Disorders, Amgen Inc., , South San Francisco, California, 94080 |
| |
Abstract: | Recombinant human lecithin‐cholesterol acyltransferase Fc fusion (huLCAT‐Fc) is a chimeric protein produced by fusing human Fc to the C‐terminus of the human enzyme via a linker sequence. The huLCAT‐Fc homodimer contains five N‐linked glycosylation sites per monomer. The heterogeneity and site‐specific distribution of the various glycans were examined using enzymatic digestion and LC‐MS/MS, followed by automatic processing. Almost all of the N‐linked glycans in human LCAT are fucosylated and sialylated. The predominant LCAT N‐linked glycoforms are biantennary glycans, followed by triantennary sugars, whereas the level of tetraantennary glycans is much lower. Glycans at the Fc N‐linked site exclusively contain typical asialobiantennary structures. HuLCAT‐Fc was also confirmed to have mucin‐type glycans attached at T407 and S409. When LCAT‐Fc fusions were constructed using a G‐S‐G‐G‐G‐G linker, an unexpected +632 Da xylose‐based glycosaminoglycan (GAG) tetrasaccharide core of Xyl‐Gal‐Gal‐GlcA was attached to S418. Several minor intermediate species including Xyl, Xyl‐Gal, Xyl‐Gal‐Gal, and a phosphorylated GAG core were also present. The mucin‐type O‐linked glycans can be effectively released by sialidase and O‐glycanase; however, the GAG could only be removed and localized using chemical alkaline β‐elimination and targeted LC‐MS/MS. E416 (the C‐terminus of LCAT) combined with the linker sequence is likely serving as a substrate for peptide O‐xylosyltransferase. HuLCAT‐Fc shares some homology with the proposed consensus site near the linker sequence, in particular, the residues underlined PPP E416GS418G G G GDK. GAG incorporation can be eliminated through engineering by shifting the linker Ser residue downstream in the linker sequence. |
| |
Keywords: | recombinant human LCAT‐Fc N‐ and O‐linked glycans site‐specific N‐linked glycan profile xylose‐based glycosaminoglycan |
|
|